As of Friday, January 09, ARS Pharmaceuticals, Inc.’s SPRY share price has surged by 18.04%, which has investors questioning if this is right time to sell.

ARS Pharmaceuticals Inc. stock rose Friday as FDA identified deficiencies in rival Aquestive's application, delaying ...

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is one of the 12 Stocks that Will Bounce Back According to Wall Street Analysts. On ...

ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to a loss of $0.13 per share a year ago. These ...

ARS Pharmaceuticals, Inc. will host a conference call and webcast on March 20, 2025, at 8:30 a.m. ET to discuss its financial results for the fourth quarter and full year of 2024, along with key ...

ARS Pharmaceuticals Inc. company and executive profile by Barron's. View the latest SPRY company infomation and executive bios.

ARS Pharmaceuticals Operations filed an antitrust lawsuit against AptarGroup on Sept. 29 in California Southern District Court alleging monopolization of critical components for Neffy, an epinephrine ...

ARS Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.35 EPS, expectations were $-0.35. Operator: Good morning and welcome to ARS Pharmaceuticals’ Conference Call.

Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Get Free Report) have been given an average recommendation of “Buy” by the six ratings firms that are presently covering the firm, Marketbeat reports ...

Good morning and welcome to ARS Pharmaceuticals Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I'll now turn the call over to Justin Chakma, ...